{"url_path":"/sec/ipsc/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-059824-index.html","accession_number":"0001104659-26-059824","cik":"0001850119","ticker":"IPSC","issuer_name":"Century Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-059824-index.html","primary_entity_key":"0001850119","primary_entity_name":"Century Therapeutics, Inc."},"word_count":139,"has_tables":true,"body_markdown":"**Item 2.02**\n**Results of Operations and Financial Condition**\n\n \n\nOn May 13, 2026, Century Therapeutics, Inc. (the “Company”)\nissued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished\nas Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe information contained in this Item 2.02 (including Exhibit 99.1)\nis being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,\nas amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated\nby reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by\nspecific reference in such filing."}